来源：新浪证券-红岸工作室 10月9日，百龙创园涨2.54%，成交额9333.30万元，换手率1.09%，总市值86.44亿元。 异动分析 代糖概念+参股银行+人民币贬值受益+专精特新 1、公司生产的健康甜味剂产品主要为阿洛酮糖，阿洛酮糖是在自然界中天然存在但含量极少的一种稀 有单糖，其甜味及口感与蔗糖相当类似或接近，但其热量却远低于蔗糖，对于肥胖以及糖尿病患者是一 种理想的蔗糖代替物。 2、2024年半年报，公司持有山东禹城农村商业银行股份有限公司 5.14%股份。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 该股筹码平均交易成本为20.44元，近期筹码关注程度减弱；目前股价靠近支撑位20.53，注意支撑位处 反弹，若跌破支撑位则可能会开启一波下跌行情。 公司简介 3、根据202 ...

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank, as well as the depreciation of the RMB [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and health sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8]. - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8]. - The company was established on December 30, 2005, and went public on April 21, 2021 [8]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and innovation [4]. - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the RMB [4]. Group 4: Stock Performance and Trading Activity - On September 30, the company's stock rose by 0.20%, with a trading volume of 64.54 million yuan and a turnover rate of 0.77%, bringing the total market capitalization to 8.43 billion yuan [1]. - The average trading cost of the stock is 20.44 yuan, with the current price approaching a resistance level of 20.15 yuan, indicating potential for a price correction if this level is not surpassed [7]. - The main capital inflow for the day was 461,300 yuan, with no significant trends in capital movement observed [5][6].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [1][2][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and healthy sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8]. - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8]. - The company has achieved a revenue of 649 million yuan in the first half of 2025, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. Group 2: Financial Performance - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial benefits [3]. Group 3: Market Position and Trends - The company is recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and market share [4]. - The company benefits from a 60.62% share of overseas revenue, positively impacted by the depreciation of the RMB [4]. Group 4: Stock Performance and Investor Sentiment - On September 29, the company's stock price fell by 1.77%, with a trading volume of 61.92 million yuan and a turnover rate of 0.73%, leading to a total market capitalization of 8.413 billion yuan [1]. - The stock has an average trading cost of 20.43 yuan, with recent buying activity indicating weak accumulation, and the stock price is approaching a resistance level of 20.11 yuan [7].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing positive market movements due to its involvement in the sugar substitute sector, its stake in a rural commercial bank, and benefits from the depreciation of the RMB, alongside its recognition as a "specialized, refined, distinctive, and innovative" enterprise [2][4]. Company Overview - Shandong Bailong Chuangyuan was established on December 30, 2005, and went public on April 21, 2021. Its main business includes the research, production, and sales of prebiotics, dietary fibers, starch sugars, and healthy sweeteners [8]. - The company's revenue composition is as follows: dietary fibers 54.15%, prebiotics 28.00%, healthy sweeteners 13.57%, and others 3.91% [8]. Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million, with a growth of 42.00% [8]. - The company has distributed a total of 183 million in dividends since its A-share listing, with 172 million distributed over the past three years [9]. Shareholding and Market Activity - As of June 30, 2025, the top ten circulating shareholders include notable funds such as Penghua New Emerging Industries Mixed Fund and Hong Kong Central Clearing Limited, indicating increased institutional interest [10]. - The stock has seen a net inflow of 7.34 million today, with a total market capitalization of 8.54 billion [5][6]. Industry Context - The company is categorized under the basic chemical industry, specifically in food and feed additives, and is part of several concept sectors including sugar substitutes and value growth [8]. - The recognition as a "specialized, refined, distinctive, and innovative" enterprise enhances its competitive edge and stability within the industry [4].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fiber, and health sweeteners, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8] - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8] Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8] - The company has distributed a total of 162 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [9] Group 3: Market Position and Strategic Advantages - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide financial leverage and strategic benefits [3] - The company’s overseas revenue accounts for 60.62% of its total revenue, benefiting from the depreciation of the RMB [4] - The company has been recognized as a "specialized and innovative" enterprise, which is a prestigious title in China, indicating its strong market position and innovation capabilities [4] Group 4: Stock Performance and Market Sentiment - On September 3, the company's stock price fell by 2.65%, with a trading volume of 132 million yuan and a turnover rate of 1.51%, resulting in a total market capitalization of 8.644 billion yuan [1] - The stock has seen a net outflow of 2.9945 million yuan from major investors today, with a lack of clear trends in major holdings [5][6]